Rosetta Genomics Ltd. (ROSG) announced Wednesday morning that Novitas informed the company that it plans to cover the company's miRview mets² assay for all Medicare beneficiaries. MiRview mets² accurately identifies the primary tumor of origin in primary and metastatic cancer.
Rosetta Genomics gapped up Wednesday and rose steadily throughout the first hour of trade. The stock finished up by 3.37 at $4.99 on the highest volume of the year and broke out to over a one-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.